PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1555478
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1555478
Targeted Sequencing Market size was valued at USD 3,588.89 Million in 2023, expanding at a CAGR of 11.9% from 2024 to 2032.
Targeted sequencing represents a swift and economical method for identifying both established and new variants within specific genes or genomic areas. When sequencing a limited number of targeted regions, PCR amplification is employed alongside Sanger sequencing. This approach provides valuable insights into particular areas of the genome. It serves as a robust tool for exploring various disease domains, including oncology, hereditary conditions, immunology, and infectious diseases. This technique enables precise and efficient targeting of specific genes, coding regions, and even segments of chromosomes.
Targeted Sequencing Market- Market Dynamics
Rising Demand for Personalized treatment strategy is projected to drive the growth of market demand
In the field of oncology, the application of targeted sequencing is becoming more prevalent for the identification of specific genetic mutations and alterations present in tumors. This advancement enables healthcare professionals to formulate personalized treatment plans that are specifically designed to align with the unique genetic characteristics of a patient's cancer. As reported by the National Center for Biotechnology Information, the ideal personalized medicine approach, which assigns therapies based on covariate values, is projected to achieve an expected success rate of around 64%. This represents a significant enhancement compared to the 50% success rate observed in both the treatment and control groups. Additionally, the emergence of technological innovations and the introduction of new products may present growth opportunities for the market. Nevertheless, concerns regarding data privacy and security could pose challenges to market expansion.
Targeted Sequencing Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.9% over the forecast period (2024-2032)
Based on product type segmentation, Services was predicted to show maximum market share in the year 2023
Based on application segmentation, Cancer was the leading type in 2023
Based on Target Capture segmentation, Targeted DNA Sequencing was the leading type in 2023
Based on Enrichment Method segmentation, Hybridization Capture was the leading type in 2023
Based on end user segmentation, Academic and Research Institutions were the leading type in 2023
Based on region, North America was the leading revenue generator in 2023
The Global Targeted Sequencing Market is segmented based on Product Type, Application, Target Capture, Enrichment Method, End User, and Region.
The market is segmented into three distinct categories according to product type: Instruments, Services, and Kits/Panels and Assays, among others. Services hold a dominant position within the market. The Targeted Sequencing Market emphasizes technologies and services designed for the selective sequencing of specific genomic regions, offering a more cost-effective and efficient alternative to whole-genome sequencing.
The market is segmented into six categories according to their applications: Cancer, Reproductive Health, Hereditary Diseases, Neurological Disorders, Infectious Diseases, Cardiovascular Diseases, Rare Diseases, and Others. Cancer holds a predominant position within the market. The Targeted Sequencing Market, particularly concerning cancer, is experiencing significant growth as targeted sequencing technologies are progressively employed to detect genetic mutations and variations linked to different cancer types.
The market is categorized into two segments according to Target Capture: Targeted DNA Sequencing, Targeted RNA Sequencing, and Other. Targeted DNA Sequencing holds a leading position in the market. This method enables the detailed examination of particular areas within the genome, offering essential information regarding genetic mutations, variations, and biomarkers.
The market is classified into two segments according to the Enrichment Method: Hybridization Capture, Amplicon Sequencing, and Other. Hybridization Capture is the leading method in this market. This technique focuses on enriching particular DNA sequences from a complex sample, thereby proving to be highly efficient for targeted sequencing.
The market is segmented into three distinct categories according to the End User: Diagnostic and Clinical Laboratories, Academic and Research Institutions, and Pharmaceutical and Biotech Companies, along with others. Academic and Research Institutions hold a dominant position within the market. These institutions play a crucial role in fostering growth and innovation in the targeted sequencing sector. Their contributions not only enhance scientific understanding but also facilitate the creation of novel clinical applications, establishing targeted sequencing as an essential resource in contemporary genomics research.
Targeted Sequencing Market- Geographical Insights
This market is geographically extensive, encompassing North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These areas are further categorized based on the countries that contribute to business activities. North America leads the market, primarily due to the widespread implementation of targeted sequencing within academic and research institutions. The region is home to several of the world's foremost academic and research organizations, whose comprehensive research initiatives and substantial funding levels facilitate the swift adoption and progression of targeted sequencing technologies. According to the National Science Foundation, the research and experimental development (R&D) expenditure in the United States reached USD 667 billion in 2019, with an estimated increase to USD 708 billion in 2020. Europe holds the second largest region for market growth, attributed to the high adoption rates in clinical environments.
The Targeted Sequencing Market is characterized by a dynamic competitive landscape among prominent players, driven by rapid technological advancements, the demand for cost-effective solutions, and a growing interest in precision medicine. Companies are actively working to expand their presence in emerging markets, where there is an increasing need for genomic research and clinical diagnostics. Furthermore, organizations often form strategic partnerships with academic institutions, research entities, and biotechnology firms to jointly create new products or enhance current offerings. These collaborations can promote the swift adoption of cutting-edge technologies and strengthen a company's position in the market.
In January 2023, Agilent Technologies Inc. declared its acquisition of Avida Biomed, a nascent life sciences firm specializing in the development of advanced target enrichment workflows. These workflows possess distinctive features that cater to clinical researchers employing next-generation sequencing (NGS) methodologies in cancer research.
In May 2024, Illumina Inc. revealed the research it plans to showcase at the American Society of Clinical Oncology conference, scheduled for May 31 to June 4 in Chicago. A prevalent theme in the presented research is the company's initiative to enhance the utilization of genomic testing in oncology research. A significant portion of the research was conducted through collaborative efforts, with partners including Labcorp and the Sarah Cannon Research Institute.